CARex-VP22 and CARex-Tat improve adenoviral infection of permissive tumor cell lines. Different target cell types were overlaid with medium containing purified CARex-VP22 or CARex-Tat, respectively, at a concentration of 2 nM. AdLacZ (MOI, 10) was then added, and infection was carried out for 30 min or 4 h as indicated. After 48 h of incubation, infection efficacy was determined by β-galactosidase assays of extracts from infected cells.